Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-06-03
|
AG-120 (ivosidenib) isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor |
IDH1 gene-mutated cholangiocarcinoma |
3 |
Agios Pharmaceuticals (USA -MA) |
Cancer - Oncology - Rare diseases |
2017-06-03
|
LOXO- 101 (larotrectinib - (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
pediatric patients with advanced solid or primary central nervous system tumors |
1 |
Loxo Oncology (USA - CT) |
Cancer - Oncology |
2017-06-03
|
abemaciclib (LY2835219) |
hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer |
3 |
Eli Lilly (USA - IN) |
Cancer - Oncology |
2017-06-03
|
LOXO- 101 (larotrectinib - (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
NTRK fusion-positive tumors |
2 |
Loxo Oncology (USA - CT) |
Cancer - Oncology |
2017-06-03
|
Xilonix™ |
advanced colorectal cancer |
3 |
XBiotech (USA - TX) |
Cancer - Oncology |
2017-06-02
|
Opdivo® (nivolumab) |
advanced cervical, vaginal and vulvar cancers associated with infection by the human papillomavirus (HPV). |
1-2 |
BMS (USA - NY) |
Cancer - Oncology |
2017-06-02
|
MOR208 plus bendamustine |
patients with relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL) who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) |
2-3 |
MorphoSys (Germany) |
Cancer - Oncology |
2017-06-01
|
BioChaperone® Glucagon |
type 1 diabetes |
1 |
Adocia (France) |
Metabolic diseases |
2017-06-01
|
BioChaperone® Lispro U100 with Fiasp® (faster-acting insulin aspart) and Novolog®(insulin aspart) |
type 1 diabetes |
1 |
Adocia (France) |
Metabolic diseases |
2017-06-01
|
C-Scape (ACHN-383 and ACHN-789) |
|
1 |
Achaogen (US - CA) |
Infectious diseases |
2017-06-01
|
luspatercept |
beta-thalassemia |
3 |
Celgene (USA - NJ) Acceleron Pharma (USA - CA) |
Rare diseases - Genetic diseases - Hematological diseases |
2017-06-01
|
luspatercept |
myelodysplastic syndromes (MDS) |
3 |
Celgene (USA - NJ) Acceleron Pharma (USA - MA) |
Cancer - Oncology - Rare diseases - Genetic diseases |
2017-05-31
|
RGX-314 |
wet age-related macular degeneration (wet AMD) |
1 |
RegenXBio (USA - MD) |
Ophtalmological diseases |
2017-05-30
|
MP0250 |
multiple myeloma |
2 |
Molecular Partners (Switzerland) |
Cancer - Oncology |
2017-05-30
|
SYL1001 (tivanisiran) |
dry eye syndrome |
3 |
Sylentis (Spain) |
Ophtalmological diseases |
2017-05-30
|
LOXO-195 |
cancers that have acquired resistance to initial TRK therapy |
1-2 |
Loxo Oncology (USA - CT) |
Cancer - Oncology |
2017-05-30
|
|
mucopolysaccharidosis type IIIA (Sanfilippo B syndrome) |
observational |
Lysogene (France) |
Rare diseases - Genetic diseases |
2017-05-27
|
doravirine (MK-1439) |
HIV-1 infection |
3 |
Merck&Co (USA - NJ) |
Infectious diseases |
2017-05-27
|
Ofev® (nintedanib) |
idiopathic pulmonary fibrosis (IPF) |
3 |
Boehringer Ingelheim (Germany) |
Lung diseases - Respiratory diseases |
2017-05-25
|
NY-ESO SPEAR T-cells targeting NY-ESO in combination with Keytruda® (pembrolizumab) |
relapsed and/or refractory multiple myeloma |
1 |
Adaptimmune (UK) |
Cancer - Oncology |